Fox Run Management L.L.C. Acquires New Holdings in Illumina, Inc. $ILMN

Key Points

• Fox Run Management L.L.C. acquired 11,533 shares of Illumina, Inc., valued at approximately $915,000, indicating institutional interest in the stock during the 1st quarter.
• Recent analysts' ratings for Illumina include Piper Sandler lowering its target price from $190 to $185 while Royal Bank Of Canada increased its target from $118 to $126, highlighting mixed market perspectives.
• Illumina's latest quarterly earnings reported an EPS of $1.19, which exceeded expectations, despite a 4.8% decline in revenue year-over-year.

Fox Run Management L.L.C. bought a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 11,533 shares of the life sciences company's stock, valued at approximately $915,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Mariner LLC grew its position in Illumina by 13.5% in the fourth quarter. Mariner LLC now owns 10,921 shares of the life sciences company's stock valued at $1,459,000 after acquiring an additional 1,298 shares in the last quarter. CreativeOne Wealth LLC acquired a new stake in shares of Illumina during the fourth quarter worth approximately $248,000. Jump Financial LLC grew its position in shares of Illumina by 260.0% during the fourth quarter. Jump Financial LLC now owns 7,865 shares of the life sciences company's stock worth $1,051,000 after buying an additional 5,680 shares in the last quarter. Zacks Investment Management grew its position in shares of Illumina by 3.5% during the fourth quarter. Zacks Investment Management now owns 23,210 shares of the life sciences company's stock worth $3,102,000 after buying an additional 786 shares in the last quarter. Finally, Farringdon Capital Ltd. acquired a new stake in shares of Illumina during the fourth quarter worth approximately $206,000. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Stock Performance

ILMN stock traded down $1.2510 during mid-day trading on Wednesday, reaching $100.3490. The company had a trading volume of 712,404 shares, compared to its average volume of 2,341,988. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $15.42 billion, a P/E ratio of 12.71, a P/E/G ratio of 2.26 and a beta of 1.37. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The stock's 50-day simple moving average is $97.39 and its two-hundred day simple moving average is $89.42.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.17. The company had revenue of $1.06 billion for the quarter, compared to analysts' expectations of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm's quarterly revenue was down 4.8% compared to the same quarter last year. During the same period last year, the business posted $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Royal Bank Of Canada raised their price target on shares of Illumina from $118.00 to $126.00 and gave the stock an "outperform" rating in a research report on Friday, August 1st. Piper Sandler decreased their price target on shares of Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a research report on Thursday, May 15th. Canaccord Genuity Group raised their price target on shares of Illumina from $99.00 to $105.00 and gave the stock a "hold" rating in a research report on Friday, August 1st. Citigroup downgraded shares of Illumina from a "hold" rating to a "strong sell" rating and decreased their price target for the stock from $85.00 to $80.00 in a research report on Wednesday, July 9th. Finally, Daiwa America cut Illumina from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 12th. Seven equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Illumina has an average rating of "Hold" and a consensus price target of $124.58.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.